Just over half of multitarget stool DNA tests ordered are completed, with age and race influencing compliance as well as ...

They’re non-invasive with none of the dreaded prep. But are recently approved home tests for colon cancer as effective as ...

Guardant Health, Inc. (NASDAQ:GH) announced that Palmetto GBA, a Medicare administrative contractor that administers the ...

A blood-based epigenetic test for colon cancer has been launched in Europe ... Epigenomics detects methylation patterns in cell-free DNA in blood plasma. The assay converts all nonmethylated ...

Adding serial circulating tumor DNA (ctDNA) assays to standard of care imaging surveillance had limited clinical benefits in ...

Guardant Health stock hit a 13-month high Tuesday after Medicare officials agreed to pay for the company's colon cancer blood test.

The World Health Organization estimates that around 900,000 people each year die of colorectal ... tumour DNA (ctDNA), with one study finding that positive ctDNA tests predicted recurrence in ...

Despite the availability of several noninvasive tests for colorectal cancer, prioritizing blood-based tests may result in ...

A1, a new biomarker, improves early detection of colorectal cancer with higher accuracy and less invasiveness.